Literature DB >> 36134835

ICD indication in hypertrophic cardiomyopathy: which algorithm to use?

Marcelo Antônio Oliveira Santos-Veloso1,2, Ândrea Virgínia Ferreira Chaves1,2,3, Eveline Barros Calado4, Manuel Markman5, Lucas Soares Bezerra1,2, Sandro Gonçalves de Lima2,4, Brivaldo Markman Filho4, Dinaldo Cavalcanti de Oliveira1.   

Abstract

OBJECTIVE: This study aimed to evaluate the agreement in the indication of implantable cardioverter-defibrillators in patients with Hypertrophic cardiomyopathy, as per the 2014 European Society of Cardiology and 2020 American Heart Association recommendations, and evaluate fragmented QRS as a predictor of cardiovascular outcome.
METHODS: Retrospective cohort with 81 patients was evaluated between 2019 and 2021. Patients with hypertrophic cardiomyopathy ≥16 years old were included. Exclusion criteria include secondary myocardiopathy and follow-up <1 year. Kappa coefficient was used to determine the agreement. Survival and incidence curves were determined by Kaplan-Meier method. A p<0.05 was considered significant.
RESULTS: The fragmented QRS was identified in 44.4% of patients. There were no differences between patients with and without fragmented QRS regarding clinical parameters, echocardiography, fibrosis, and sudden cardiac death risk. During follow-up of 4.8±3.4 years, there was no sudden cardiac death, but 20.6% patients with implantable cardioverter-defibrillator had at least one appropriate shock. Three of the seven appropriate shocks occurred in European Society of Cardiology low- to moderate-risk patients. Three shocks occurred in moderate-risk patients and four in American Heart Association high-risk patients. Overall recommendations agreement was 64% with a kappa of 0.270 (p=0.007). C-statistic showed no differences regarding the incidence of appropriate shock (p=0.644).
CONCLUSION: sudden cardiac death risk stratification algorithms present discrepancies in implantable cardioverter-defibrillator indication, both with low accuracy.

Entities:  

Mesh:

Year:  2022        PMID: 36134835      PMCID: PMC9574997          DOI: 10.1590/1806-9282.20220199

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.712


  19 in total

1.  Risk Markers and Appropriate Implantable Defibrillator Therapy in Hypertrophic Cardiomyopathy.

Authors:  Peter Magnusson; Fredrik Gadler; Per Liv; Stellan Mörner
Journal:  Pacing Clin Electrophysiol       Date:  2016-01-21       Impact factor: 1.976

2.  Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy: Potential for refinement of current criteria.

Authors:  Milind Y Desai; Nicholas G Smedira; Ashwat Dhillon; Ahmad Masri; Oussama Wazni; Mohamad Kanj; Kimi Sato; Maran Thamilarasan; Zoran B Popovic; Harry M Lever
Journal:  J Thorac Cardiovasc Surg       Date:  2018-04-12       Impact factor: 5.209

Review 3.  Sudden Cardiac Death in Hypertrophic Cardiomyopathy.

Authors:  Daria M Adamczak; Zofia Oko-Sarnowska
Journal:  Cardiol Rev       Date:  2018 May/Jun       Impact factor: 2.644

Review 4.  Hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Martin S Maron
Journal:  Lancet       Date:  2012-08-06       Impact factor: 79.321

5.  Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis.

Authors:  Constantinos O'Mahony; Mohammed Majid Akhtar; Zacharias Anastasiou; Oliver P Guttmann; Pieter A Vriesendorp; Michelle Michels; Damiano Magrì; Camillo Autore; Adrián Fernández; Juan Pablo Ochoa; Kevin M W Leong; Amanda M Varnava; Lorenzo Monserrat; Aristides Anastasakis; Pablo Garcia-Pavia; Claudio Rapezzi; Elena Biagini; Juan Ramon Gimeno; Giuseppe Limongelli; Rumana Z Omar; Perry M Elliott
Journal:  Heart       Date:  2018-10-26       Impact factor: 5.994

6.  Assessment of the association between the presence of fragmented QRS and the predicted risk score of sudden cardiac death at 5 years in patients with hypertrophic cardiomyopathy.

Authors:  Sinem Özyılmaz; Özgür Akgül; Hüseyin Uyarel; Hamdi Pusuroğlu; Muammer Karayakalı; Mehmet Gül; Mustafa Çetin; Hulusi Satılmışoğlu; Aydın Yıldırım; İhsan Bakır
Journal:  Anatol J Cardiol       Date:  2017-05-30       Impact factor: 1.596

7.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Authors:  Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Philippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; William J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

Review 8.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Authors:  Steve R Ommen; Seema Mital; Michael A Burke; Sharlene M Day; Anita Deswal; Perry Elliott; Lauren L Evanovich; Judy Hung; José A Joglar; Paul Kantor; Carey Kimmelstiel; Michelle Kittleson; Mark S Link; Martin S Maron; Matthew W Martinez; Christina Y Miyake; Hartzell V Schaff; Christopher Semsarian; Paul Sorajja
Journal:  Circulation       Date:  2020-11-20       Impact factor: 29.690

9.  Quantitative fragmented QRS has a good diagnostic value on myocardial fibrosis in hypertrophic obstructive cardiomyopathy based on clinical-pathological study.

Authors:  Xuanye Bi; Chengzhi Yang; Yunhu Song; Jiansong Yuan; Jingang Cui; Fenghuan Hu; Shubin Qiao
Journal:  BMC Cardiovasc Disord       Date:  2020-06-18       Impact factor: 2.298

10.  Discrepancy between International Guidelines on the Criteria for Primary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy.

Authors:  Beatriz Piva E Mattos; Fernando Luís Scolari; Henrique Iahnke Garbin
Journal:  Arq Bras Cardiol       Date:  2020-08-28       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.